Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

Compare

1,402 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IONS Analyst Ratings

Moderate Buy

16 Buy

4 Hold

1 Sell

Based on 21 analysts giving stock ratings to

Ionis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$71.51

▲(17.21% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $71.51 with a high forecast of $116.76 and a low forecast of $43.00. The average price target represents a 17.21% change from the last price of $61.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","117":"$117","48.75":"$48.8","71.5":"$71.5","94.25":"$94.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":116.76,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$116.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.51,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$43.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,48.75,71.5,94.25,117],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.49,62.049230769230775,66.60846153846154,71.1676923076923,75.72692307692307,80.28615384615385,84.84538461538462,89.40461538461538,93.96384615384616,98.52307692307693,103.0823076923077,107.64153846153846,112.20076923076923,{"y":116.76,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.49,58.56846153846154,59.64692307692308,60.72538461538462,61.80384615384616,62.8823076923077,63.96076923076924,65.03923076923077,66.11769230769231,67.19615384615385,68.27461538461539,69.35307692307693,70.43153846153847,{"y":71.51,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.49,56.37538461538462,55.260769230769235,54.14615384615385,53.03153846153846,51.91692307692308,50.80230769230769,49.68769230769231,48.573076923076925,47.458461538461535,46.34384615384616,45.22923076923077,44.114615384615384,{"y":43,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":47.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.07,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.76,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.26,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.11,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.49,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$116.76

Average Price Target$71.51

Lowest Price Target$43.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gena Wang

Barclays

$78→$80

Buy

31.13%

Upside

Reiterated

09/23/25

Ionis Pharmaceuticals (IONS) Receives a Buy from Barclays

Yaron Werber

TD Cowen

$59

Buy

-3.29%

Downside

Reiterated

09/22/25

Ionis Pharmaceuticals (IONS) Gets a Buy from TD Cowen

Myles Minter

William Blair

$116.76

Buy

91.38%

Upside

Reiterated

09/22/25

Buy Rating Affirmed for Ionis Pharmaceuticals Amid Promising Phase III Results for Zilganersen in Treating Alexander Disease

Jason Gerberry

Bank of America Securities

$81→$83

Buy

36.04%

Upside

Reiterated

09/22/25

Bank of America Securities Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Gary Nachman

Raymond James

$68→$75

Buy

22.93%

Upside

Reiterated

09/22/25

Ionis Pharmaceuticals price target raised to $75 from $68 at Raymond JamesIonis Pharmaceuticals price target raised to $75 from $68 at Raymond James

Mitchell Kapoor

H.C. Wainwright

$95

Buy

55.71%

Upside

Reiterated

09/22/25

Ionis Pharmaceuticals: Strategic Positioning and Growth Potential with Olezarsen's EU Approval and Promising sHTG Market ProspectsValuation and Risks. Using a 9% discount rate and 2% terminal growth rate, our discounted cash flow (DCF) analysis results in an EV of ~$15.7B and a 12-month price objective of $95 per share.

Mani Foroohar

Leerink Partners

$62→$63

Buy

3.26%

Upside

Reiterated

09/15/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Eli Lilly & Co (NYSE: LLY) and Revvity (NYSE: RVTY)

Luca Issi

RBC Capital

$80

Buy

31.13%

Upside

Reiterated

09/08/25

RBC Capital Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

David Lebowitz

Citi

$69→$84

Buy

37.68%

Upside

Reiterated

09/04/25

Ionis Pharmaceuticals price target raised to $84 from $69 at CitiIonis Pharmaceuticals price target raised to $84 from $69 at Citi

William Pickering

Bernstein

$42→$50

Hold

-18.05%

Downside

Reiterated

09/03/25

Bernstein Sticks to Its Hold Rating for Ionis Pharmaceuticals (IONS)Bernstein SocGen Group analyst William Pickering raised the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $50.00 (from $42.00) while maintaining a Market Perform rating.

Kostas Biliouris

BMO Capital

$40→$70

Buy

14.74%

Upside

Upgraded

09/03/25

Ionis Pharmaceuticals: Promising Pipeline and Potential Profitability Drive Buy Rating

Michael Ulz

Morgan Stanley

$62→$71

Buy

16.37%

Upside

Reiterated

09/03/25

Ionis Pharmaceuticals: Strong Buy Rating Backed by Promising Phase 3 Study Results for Olezarsen

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$40→$45

Sell

-26.24%

Downside

Reiterated

09/03/25

Ionis Pharmaceuticals (IONS) Receives a Sell from Goldman Sachs

Joseph Stringer

Needham

$55→$70

Buy

14.74%

Upside

Reiterated

09/02/25

Ionis Pharmaceuticals' Olezarsen Triumphs in Phase 3 Trials, Analyst Raises Price Target

Jessica Fye

J.P. Morgan

$49

Hold

-19.69%

Downside

Reiterated

09/02/25

Ionis Pharmaceuticals: Balancing Promising Trial Results with Market Uncertainties

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gena Wang

Barclays

$78→$80

Buy

31.13%

Upside

Reiterated

09/23/25

Ionis Pharmaceuticals (IONS) Receives a Buy from Barclays

Yaron Werber

TD Cowen

$59

Buy

-3.29%

Downside

Reiterated

09/22/25

Ionis Pharmaceuticals (IONS) Gets a Buy from TD Cowen

Myles Minter

William Blair

$116.76

Buy

91.38%

Upside

Reiterated

09/22/25

Buy Rating Affirmed for Ionis Pharmaceuticals Amid Promising Phase III Results for Zilganersen in Treating Alexander Disease

Jason Gerberry

Bank of America Securities

$81→$83

Buy

36.04%

Upside

Reiterated

09/22/25

Bank of America Securities Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

Gary Nachman

Raymond James

$68→$75

Buy

22.93%

Upside

Reiterated

09/22/25

Ionis Pharmaceuticals price target raised to $75 from $68 at Raymond JamesIonis Pharmaceuticals price target raised to $75 from $68 at Raymond James

Mitchell Kapoor

H.C. Wainwright

$95

Buy

55.71%

Upside

Reiterated

09/22/25

Mani Foroohar

Leerink Partners

$62→$63

Buy

3.26%

Upside

Reiterated

09/15/25

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (NASDAQ: IONS), Eli Lilly & Co (NYSE: LLY) and Revvity (NYSE: RVTY)

Luca Issi

RBC Capital

$80

Buy

31.13%

Upside

Reiterated

09/08/25

RBC Capital Sticks to Their Buy Rating for Ionis Pharmaceuticals (IONS)

David Lebowitz

Citi

$69→$84

Buy

37.68%

Upside

Reiterated

09/04/25

Ionis Pharmaceuticals price target raised to $84 from $69 at CitiIonis Pharmaceuticals price target raised to $84 from $69 at Citi

William Pickering

Bernstein

$42→$50

Hold

-18.05%

Downside

Reiterated

09/03/25

Kostas Biliouris

BMO Capital

$40→$70

Buy

14.74%

Upside

Upgraded

09/03/25

Ionis Pharmaceuticals: Promising Pipeline and Potential Profitability Drive Buy Rating

Michael Ulz

Morgan Stanley

$62→$71

Buy

16.37%

Upside

Reiterated

09/03/25

Ionis Pharmaceuticals: Strong Buy Rating Backed by Promising Phase 3 Study Results for Olezarsen

Unknown Analyst

Goldman Sachs

Not Ranked

Goldman Sachs

$40→$45

Sell

-26.24%

Downside

Reiterated

09/03/25

Ionis Pharmaceuticals (IONS) Receives a Sell from Goldman Sachs

Joseph Stringer

Needham

$55→$70

Buy

14.74%

Upside

Reiterated

09/02/25

Ionis Pharmaceuticals' Olezarsen Triumphs in Phase 3 Trials, Analyst Raises Price Target

Jessica Fye

J.P. Morgan

$49

Hold

-19.69%

Downside

Reiterated

09/02/25

Ionis Pharmaceuticals: Balancing Promising Trial Results with Market Uncertainties

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ionis Pharmaceuticals

1 Month

xxx

Success Rate

13/20 ratings generated profit

Average Return

+4.15%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +4.15% per trade.

3 Months

xxx

Success Rate

21/34 ratings generated profit

Average Return

+4.78%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.76% of your transactions generating a profit, with an average return of +4.78% per trade.

1 Year

Gary NachmanRaymond James

Success Rate

16/20 ratings generated profit

Average Return

+28.16%

reiterated a buy rating yesterday

Copying Gary Nachman's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +28.16% per trade.

2 Years

xxx

Success Rate

33/34 ratings generated profit

Average Return

+30.07%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 97.06% of your transactions generating a profit, with an average return of +30.07% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IONS has received 54 Buy Ratings, 21 Hold Ratings, and 1 Sell Ratings. IONS average Analyst price target in the past 3 months is 71.51.

Each month's total comprises the sum of three months' worth of ratings.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$1.22 with a range of -$1.53 to -$0.69. The previous quarter’s EPS was $0.70. IONS beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.19% of the time in the same period. In the last calendar year IONS has Outperformed its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $130.50M with a range of $111.00M to $172.61M. The previous quarter’s sales results were $452.05M. IONS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.39% of the time in the same period. In the last calendar year IONS has Outperformed its overall industry.

IONS Stock Forecast FAQ

What is IONS’s average 12-month price target, according to analysts?

Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is 71.51.

What is IONS’s upside potential, based on the analysts’ average price target?

Ionis Pharmaceuticals has 17.21% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IONS a Buy, Sell or Hold?

Ionis Pharmaceuticals has a consensus rating of Moderate Buy which is based on 16 buy ratings, 4 hold ratings and 1 sell ratings.

What is Ionis Pharmaceuticals’s price target?

The average price target for Ionis Pharmaceuticals is 71.51. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $116.76 ,the lowest forecast is $43.00. The average price target represents 17.21% Increase from the current price of $61.01.

What do analysts say about Ionis Pharmaceuticals?

Ionis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of IONS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

IONS Analyst Ratings

IONS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ionis Pharmaceuticals

IONS Analyst Recommendation Trends

IONS Financial Forecast

IONS Earnings Forecast

IONS Sales Forecast

IONS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts